Avacopan — Time to Replace Glucocorticoids?

In recent decades, substantial advances in the treatment of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis have led to a decrease in disease-related morbidity and mortality. The regimen for inducing remission in patients with severe ANCA-associated vasculitis has evolved on the basis of data from randomized clinical trials and typically consists of a tapering course of glucocorticoids in combination with cyclophosphamide or rituximab.1 Despite these advances, glucocorticoids have remained an anchoring medication in updated regimens, and they contribute to treatment-related toxic effects. Along with evaluation of the efficacy and safety of newer agents such as rituximab, there has been a drive to . . .